sacituzumab tirumotecan
Commercial- Indications
- Non-small cell lung cancer
Company intelligence / Profile preview
KLUS Pharma
Princeton, New Jersey, United Stateskluspharma.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
KLUS Pharma has multiple products in clinical development with one approved product in China (Sacituzumab Tirumotecan/sac-TMT for EGFR-mutant NSCLC). Their TROP2 ADC (SKB264) and HER2 ADC (A166) have progressed to clinical trials in the US.
- Therapeutic areas
- GastroenterologyOncologyImmunologyCardiovascular
- Modalities
- Monoclonal AntibodiesBispecific AntibodiesAntibody-Drug Conjugates (ADCs)Small MoleculesRadionuclide-Drug Conjugates (RDCs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Seeking ex-China partnerships for their pipeline
Beyond the preview
Go deeper on KLUS Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KLUS Pharma.